Piramal Pharma Limited Cash Flow-to-Debt Ratio
Piramal Pharma Limited cash flow-to-debt ratio. Piramal Pharma Limited (PPLPHARMA) has a Cash Flow-to-Debt Ratio of 0.11x as of September 2025, meaning its operating cash flow of Rs8.90 Billion could theoretically repay 0% of its total liabilities (Rs81.16 Billion) in one year. Check PPLPHARMA total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Piramal Pharma Limited (2021–2026)
Cash flow-to-debt ratio of Piramal Pharma Limited from 2021 to 2026. Historical debt coverage capacity for Piramal Pharma Limited across 6 annual periods. Check PPLPHARMA cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Piramal Pharma Limited Cash Flow-to-Debt Ratio by Year (2021–2026)
Piramal Pharma Limited cash flow-to-debt ratio by year from 2021 to 2026. Year-by-year debt coverage analysis for Piramal Pharma Limited. For the full cash flow conversion analysis, see Piramal Pharma Limited cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (INR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | 0.14x | Rs14.00 Billion | Rs98.02 Billion | ▲ +20.8% |
| 2025 | 0.12x | Rs8.92 Billion | Rs75.52 Billion | ▼ -13.0% |
| 2024 | 0.14x | Rs10.05 Billion | Rs74.00 Billion | ▲ +117.4% |
| 2023 | 0.06x | Rs4.84 Billion | Rs77.49 Billion | ▲ +49.3% |
| 2022 | 0.04x | Rs2.55 Billion | Rs61.00 Billion | ▲ +99.5% |
| 2021 | 0.02x | Rs347.20 Million | Rs16.56 Billion | — |